U.S. Markets closed

BioTime, Inc. (BTX)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
3.30+0.22 (+7.14%)
At close: 4:00PM EDT

3.37 0.06 (1.97%)
After hours: 4:07PM EDT

People also watch
ASTNNVCISCOCURCYTX

BioTime, Inc.

1010 Atlantic Avenue
Suite 102
Alameda, CA 94501
United States
510-521-3390
http://www.biotimeinc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees100

Key Executives

NameTitlePayExercisedAge
Dr. Michael D. West Ph.D.Co-Chief Exec. Officer, Pres and Director758.57kN/A64
Mr. Aditya P. MohantyCo-Chief Exec. Officer and Director763.25kN/A50
Mr. Russell L. SkibstedChief Financial Officer493.25kN/A58
Ms. Judith SegallVP of Admin. and Sec.N/AN/A64
Mr. Pedro LichtingerChief Exec. Officer of Asterias Biotherapeutics Inc and Pres of Asterias Biotherapeutics IncN/AN/A63
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Corporate Governance

BioTime, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.